Phase I-II Clinical Trial for the Evaluation of Brentuximab Vedotin Plus Etoposide, Solumoderin (Methylprednisolone), High Dose ARA-C (Cytarabine) and Cisplatin in the Transplant and Post-transplant Management for Relapsed or Refractory Classical Hodgkin Lymphoma Patients
Phase of Trial: Phase I/II
Latest Information Update: 25 Apr 2019
Price : $35 *
At a glance
- Drugs Brentuximab vedotin (Primary) ; Cisplatin; Cytarabine; Etoposide; Methylprednisolone
- Indications Hodgkin's disease
- Focus Adverse reactions; Therapeutic Use
- Acronyms GELTAMO
- 23 Apr 2019 Status changed from active, no longer recruiting to completed.
- 15 Feb 2019 The trial has been completed in Spain (End Date;2019-01-14).
- 07 Feb 2019 Planned End Date changed from 1 Jan 2019 to 1 Mar 2019.